Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme.
about
Dendritic cell vaccines for brain tumorsExploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell VaccinesVaccine therapies in malignant gliomaImmunotherapy advances for glioblastomaImmunotherapy for primary brain tumors: no longer a matter of privilegeAntibody, T-cell and dendritic cell immunotherapy for malignant brain tumorsCellular immunotherapy for pediatric solid tumorsAn update on vaccine therapy and other immunotherapeutic approaches for glioblastomaHuman monocytes undergo excessive apoptosis following temozolomide activating the ATM/ATR pathway while dendritic cells and macrophages are resistantMonitoring of regulatory T cell frequencies and expression of CTLA-4 on T cells, before and after DC vaccination, can predict survival in GBM patientsInflammation and Gliomagenesis: Bi-Directional Communication at Early and Late Stages of Tumor Progression.DCVax®-L--developed by Northwest BiotherapeuticsTumour Relapse Prediction Using Multiparametric MR Data Recorded during Follow-Up of GBM Patients.Immunocompetent murine models for the study of glioblastoma immunotherapyA phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients.Cytokine responsiveness of CD8(+) T cells is a reproducible biomarker for the clinical efficacy of dendritic cell vaccination in glioblastoma patients.Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstemExperimental approaches for the treatment of malignant gliomas.Immunotherapy of malignant gliomas using autologous and allogeneic tissue cells.Overview of cellular immunotherapy for patients with glioblastoma.Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial.Cellular and vaccine therapeutic approaches for gliomasStratification according to HGG-IMMUNO RPA model predicts outcome in a large group of patients with relapsed malignant glioma treated by adjuvant postoperative dendritic cell vaccination.An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiformeImmunotherapy coming of age: what will it take to make it standard of care for glioblastoma?Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.α-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial.Primed tumor-reactive multifunctional CD62L+ human CD8+ T cells for immunotherapyInduction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcelluloImmune therapeutic targeting of glioma cancer stem cells.Immunotherapy of brain cancers: the past, the present, and future directions.Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme.Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy.Reirradiation as part of a salvage treatment approach for progressive non-pontine pediatric high-grade gliomas: preliminary experiences from the German HIT-HGG study group.Establishment and characterization of primary glioblastoma cell lines from fresh and frozen material: a detailed comparison.Immunotherapy of rat glioma without accumulation of CD4(+)CD25(+)FOXP3(+) regulatory T cellsTumors of the central nervous system in children and adolescents.The future of high-grade glioma: Where we are and where are we going.Combined Flt3L/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen.The value of EGFRvIII as the target for glioma vaccines.
P2860
Q24641823-8343B901-46C9-49CF-A0A1-82631126403FQ26772715-1298F705-16F9-4620-A45D-96E5E2AF5CD5Q26829328-0BBA26D5-CA01-451A-BF42-F136F15F0081Q26866513-514E8C1D-9AE1-40F6-9790-0566557ED010Q27002510-517A965C-CA57-48F4-9C5B-8F5C1650B2CEQ27011298-78D2B2D3-9C4D-4140-B2EC-4B32B2548EEEQ27014912-0C7324DE-D74A-4F2C-9BF2-37B8AF70FB29Q27024830-5A7B87D2-B2C0-4DFD-A312-B8C9A6C2B96AQ28480882-7095090A-5D01-4D9A-9198-A26CA034D9DFQ28730798-6FE0B8E1-32E5-4FB8-A112-9545D4F03BC7Q30414501-AC6E84FF-D79E-4170-B429-CD30A9EDAF95Q30875456-EC5B0726-D596-4B6E-B83A-E4D459BABC77Q30998509-2F35C027-38A5-4D20-956E-CBE15F1850F3Q33574853-FCCE93E6-0408-4FD0-B934-8E76070D7B9BQ33668084-CE8DC9CB-5DF8-4475-98D7-58B9B620FC60Q33691858-E893590F-0C84-4F55-A398-1774EFA2AECFQ33796170-87B7448D-9830-42F9-87C1-A33777D0A005Q34127138-7640F560-0C7A-4BBA-A184-5503F09AC560Q34140756-B2798E7B-B76A-4D63-B3C2-CE237BB12CA1Q34189694-8898E3A5-2B24-4AEB-9940-1B868F50EB70Q34242939-2C38009C-1B94-4F58-882F-DF762474A138Q34243550-57E19E22-A0E0-4AD9-8865-5E20DB2FF811Q34260758-A738E4B6-0417-4334-B0C0-5733F3F91F1AQ34346944-42E7283B-44A1-447E-8B1E-8C9A50BC8D87Q34480557-D718987B-0937-4A6C-B3A9-9C545C3871B7Q34488771-8A33E388-9A43-4313-9C11-0DE12404A29BQ34523918-7E84BD0A-311B-4584-AFC5-3FCAD34E4DC7Q34594769-47601184-5C1A-4359-B98A-B9084C59BFF5Q34666875-733DBDC9-B148-4101-8F2F-393D1EB9C60DQ34676437-D6B8BD0D-1C5F-4046-9BA8-6B0A71099F6AQ34701587-B6608414-DC6C-4F75-89F1-027D0A03D512Q34722857-F6A4BF23-8D10-487D-B3D7-4D9808EB6F48Q34764143-3F47DA5B-EFF5-4102-B920-F4F1B39333C4Q34812560-46C0EC2F-9A99-4D9F-A8A9-36301A7C9B32Q34948627-DCE5142C-F410-4807-BEA2-D05ED0F4BF26Q35020804-00CB958F-A0A0-4BCB-A810-404EF5AF62AAQ35069870-7C8B8965-9510-4AE1-A861-8669669765A8Q35114090-250C95F5-E104-41A2-8F3B-76F5AD4C5055Q35285859-FDD177D6-86D1-4A0F-BFFE-FA0B5787A275Q35627573-F96DB5AC-F81C-47C4-8470-3EB1961326B8
P2860
Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Postoperative adjuvant dendrit ...... apsed glioblastoma multiforme.
@en
Postoperative adjuvant dendrit ...... apsed glioblastoma multiforme.
@nl
type
label
Postoperative adjuvant dendrit ...... apsed glioblastoma multiforme.
@en
Postoperative adjuvant dendrit ...... apsed glioblastoma multiforme.
@nl
prefLabel
Postoperative adjuvant dendrit ...... apsed glioblastoma multiforme.
@en
Postoperative adjuvant dendrit ...... apsed glioblastoma multiforme.
@nl
P2093
P50
P1476
Postoperative adjuvant dendrit ...... apsed glioblastoma multiforme.
@en
P2093
Eckhart Kaempgen
Frank Van Calenbergh
Guido Wilms
Jan Goffin
Johannes E A Wolff
Johannes Van Loon
Niels Soerensen
Philippe Demaerel
Sabine Wagner
Stefaan W Van Gool
P304
P356
10.1158/1078-0432.CCR-07-4875
P407
P577
2008-05-01T00:00:00Z